Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 120

1.

Practical management of riociguat in patients with pulmonary arterial hypertension.

Halank M, Tausche K, Grünig E, Ewert R, Preston IR.

Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619868938. doi: 10.1177/1753466619868938.

2.

[Hemodynamic Definition of Pulmonary Hypertension: Commentary on the Proposed Change by the 6th World Symposium on Pulmonary Hypertension].

Rosenkranz S, Diller GP, Dumitrescu D, Ewert R, Ghofrani HA, Grünig E, Halank M, Held M, Kaemmerer H, Klose H, Kovacs G, Konstantinides S, Lang IM, Lange TJ, Leuchte H, Mayer E, Olschewski A, Olschewski H, Olsson KM, Opitz C, Schermuly RT, Seeger W, Wilkens H, Hoeper MM.

Dtsch Med Wochenschr. 2019 Sep;144(19):1367-1372. doi: 10.1055/a-0918-3772. Epub 2019 Jul 5. German.

3.

Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study).

Marra AM, Halank M, Benjamin N, Bossone E, Cittadini A, Eichstaedt CA, Egenlauf B, Harutyunova S, Fischer C, Gall H, Ghofrani HA, Hoeper MM, Lange TJ, Olsson KM, Klose H, Grünig E.

Respir Res. 2018 Dec 19;19(1):258. doi: 10.1186/s12931-018-0957-y.

4.

Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial.

Sadushi-Kolici R, Jansa P, Kopec G, Torbicki A, Skoro-Sajer N, Campean IA, Halank M, Simkova I, Karlocai K, Steringer-Mascherbauer R, Samarzija M, Salobir B, Klepetko W, Lindner J, Lang IM.

Lancet Respir Med. 2019 Mar;7(3):239-248. doi: 10.1016/S2213-2600(18)30367-9. Epub 2018 Nov 23.

PMID:
30477763
5.

Risk assessment in medically treated chronic thromboembolic pulmonary hypertension patients.

Delcroix M, Staehler G, Gall H, Grünig E, Held M, Halank M, Klose H, Vonk-Noordegraaf A, Rosenkranz S, Pepke-Zaba J, Opitz CF, Gibbs JSR, Lange TJ, Tsangaris I, Huscher D, Pittrow D, Olsson KM, Hoeper MM.

Eur Respir J. 2018 Nov 8;52(5). pii: 1800248. doi: 10.1183/13993003.00248-2018. Print 2018 Nov.

PMID:
30337446
6.

Long-term safety and outcome of intravenous treprostinil via an implanted pump in pulmonary hypertension.

Richter MJ, Harutyunova S, Bollmann T, Classen S, Gall H, Gerhardt Md F, Grimminger F, Grimminger J, Grünig E, Guth S, Halank M, Heine A, Hoeper MM, Klose H, Lange TJ, Meyer K, Neurohr C, Nickolaus K, Olsson KM, Opitz CF, Rosenkranz S, Seyfarth HJ, Warnke C, Wiedenroth C, Ghofrani HA, Ewert R.

J Heart Lung Transplant. 2018 Oct;37(10):1235-1244. doi: 10.1016/j.healun.2018.06.006. Epub 2018 Jun 21.

PMID:
30293617
7.

Risk stratification strategy and assessment of disease progression in patients with pulmonary arterial hypertension: Updated Recommendations from the Cologne Consensus Conference 2018.

Leuchte HH, Ten Freyhaus H, Gall H, Halank M, Hoeper MM, Kaemmerer H, Kähler C, Riemekasten G, Ulrich S, Schwaiblmair M, Ewert R.

Int J Cardiol. 2018 Dec 1;272S:20-29. doi: 10.1016/j.ijcard.2018.08.084. Epub 2018 Sep 13. Review.

PMID:
30266353
8.

Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018.

Hoeper MM, Apitz C, Grünig E, Halank M, Ewert R, Kaemmerer H, Kabitz HJ, Kähler C, Klose H, Leuchte H, Ulrich S, Olsson KM, Distler O, Rosenkranz S, Ghofrani HA.

Int J Cardiol. 2018 Dec 1;272S:37-45. doi: 10.1016/j.ijcard.2018.08.082. Epub 2018 Aug 25.

PMID:
30190158
9.

General measures and supportive therapy for pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018.

Grünig E, Benjamin N, Krüger U, Kaemmerer H, Harutyunova S, Olsson KM, Ulrich S, Gerhardt F, Neurohr C, Sablotzki A, Halank M, Marra AM, Kabitz HJ, Thimm G, Fliegel KG, Klose H.

Int J Cardiol. 2018 Dec 1;272S:30-36. doi: 10.1016/j.ijcard.2018.08.085. Epub 2018 Aug 27. Review.

PMID:
30190156
10.

Decompensated right heart failure, intensive care and perioperative management in patients with pulmonary hypertension: Updated recommendations from the Cologne Consensus Conference 2018.

Olsson KM, Halank M, Egenlauf B, Fistera D, Gall H, Kaehler C, Kortmann K, Kramm T, Lichtblau M, Marra AM, Nagel C, Sablotzki A, Seyfarth HJ, Schranz D, Ulrich S, Hoeper MM, Lange TJ.

Int J Cardiol. 2018 Dec 1;272S:46-52. doi: 10.1016/j.ijcard.2018.08.081. Epub 2018 Aug 26. Review.

PMID:
30190155
11.

Pulmonary hypertension due to lung diseases: Updated recommendations from the Cologne Consensus Conference 2018.

Olschewski H, Behr J, Bremer H, Claussen M, Douschan P, Halank M, Held M, Hoeper MM, Holt S, Klose H, Krüger S, Lange TJ, Reichenberger F, Skowasch D, Ulrich S, Wilkens H, Seeger W.

Int J Cardiol. 2018 Dec 1;272S:63-68. doi: 10.1016/j.ijcard.2018.08.043. Epub 2018 Aug 11. Review.

PMID:
30131231
12.

Correction to: Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH.

Gall H, Vachiéry JL, Tanabe N, Halank M, Orozco-Levi M, Mielniczuk L, Chang M, Vogtländer K, Grünig E.

Lung. 2018 Jun;196(3):313. doi: 10.1007/s00408-018-0112-z.

PMID:
29616325
13.

Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies.

Cartin-Ceba R, Halank M, Ghofrani HA, Humbert M, Mattson J, Fritsch A, Krowka M.

Pulm Circ. 2018 Apr-Jun;8(2):2045894018769305. doi: 10.1177/2045894018769305. Epub 2018 Mar 22.

14.

Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH.

Gall H, Vachiéry JL, Tanabe N, Halank M, Orozco-Levi M, Mielniczuk L, Chang M, Vogtländer K, Grünig E.

Lung. 2018 Jun;196(3):305-312. doi: 10.1007/s00408-018-0100-3. Epub 2018 Feb 22. Erratum in: Lung. 2018 Apr 3;:.

15.

The 6MWT as a prognostic tool in pulmonary arterial hypertension: results from the COMPERA registry.

Zelniker TA, Huscher D, Vonk-Noordegraaf A, Ewert R, Lange TJ, Klose H, Dumitrescu D, Halank M, Held M, Gall H, Pittrow D, Hoeper MM, Frankenstein L.

Clin Res Cardiol. 2018 Jun;107(6):460-470. doi: 10.1007/s00392-018-1207-5. Epub 2018 Jan 24.

PMID:
29368137
16.

Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study.

McLaughlin VV, Jansa P, Nielsen-Kudsk JE, Halank M, Simonneau G, Grünig E, Ulrich S, Rosenkranz S, Gómez Sánchez MA, Pulido T, Pepke-Zaba J, Barberá JA, Hoeper MM, Vachiéry JL, Lang I, Carvalho F, Meier C, Mueller K, Nikkho S, D'Armini AM.

BMC Pulm Med. 2017 Dec 28;17(1):216. doi: 10.1186/s12890-017-0563-7.

17.

Efficacy and safety of nasal high-flow oxygen in COPD patients.

Vogelsinger H, Halank M, Braun S, Wilkens H, Geiser T, Ott S, Stucki A, Kaehler CM.

BMC Pulm Med. 2017 Nov 17;17(1):143. doi: 10.1186/s12890-017-0486-3.

18.

Anxiety, Depression, and Health-Related QOL in Patients Diagnosed with PAH or CTEPH.

Pfeuffer E, Krannich H, Halank M, Wilkens H, Kolb P, Jany B, Held M.

Lung. 2017 Dec;195(6):759-768. doi: 10.1007/s00408-017-0052-z. Epub 2017 Oct 9.

PMID:
28993877
19.

Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study.

Halank M, Hoeper MM, Ghofrani HA, Meyer FJ, Stähler G, Behr J, Ewert R, Fletcher M, Colorado P, Nikkho S, Grimminger F.

Respir Med. 2017 Jul;128:50-56. doi: 10.1016/j.rmed.2017.05.008. Epub 2017 May 16.

20.

Cardiopulmonary exercise testing for detecting pulmonary arterial hypertension in systemic sclerosis.

Dumitrescu D, Nagel C, Kovacs G, Bollmann T, Halank M, Winkler J, Hellmich M, Grünig E, Olschewski H, Ewert R, Rosenkranz S.

Heart. 2017 May;103(10):774-782. doi: 10.1136/heartjnl-2016-309981. Epub 2017 Jan 6.

PMID:
28062514
21.

Safety, Tolerability and Clinical Effects of a Rapid Dose Titration of Subcutaneous Treprostinil Therapy in Pulmonary Arterial Hypertension: A Prospective Multi-Centre Trial.

Grünig E, Benjamin N, Lange TJ, Krueger U, Klose H, Neurohr C, Wilkens H, Halank M, Seyfarth HJ, Held M, Traube A, Pernow M, Grover ER, Egenlauf B, Gerhardt F, Viethen T, Rosenkranz S.

Respiration. 2016;92(6):362-370. Epub 2016 Oct 27.

22.

Clinical Relevance of Computed Tomography Pulmonary Venography.

Braun SD, Platzek I, Danowski D, Zöphel K, Weise M, Kolditz M, Katzke S, Strasser RH, Höffken G, Halank M.

Heart Lung Circ. 2016 Dec;25(12):1154-1163. doi: 10.1016/j.hlc.2016.04.023. Epub 2016 Jul 9. Review.

23.

[Pulmonary hypertension due to chronic lung disease: Recommendations of the Cologne Consensus Conference 2016].

Olschewski H, Behr J, Bremer H, Claussen M, Douschan P, Halank M, Held M, Hoeper MM, Holt S, Klose H, Krüger S, Lange TJ, Reichenberger F, Skowasch D, Ulrich S, Wilkens H, Seeger W.

Dtsch Med Wochenschr. 2016 Oct;141(S 01):S57-S61. Epub 2016 Oct 19. German.

PMID:
27760451
24.

[Decompensated right heart failure, intensive care and perioperative management in patients with pulmonary hypertension].

Olsson KM, Halank M, Egenlauf B, Fistera D, Gall H, Kaehler C, Kortmann K, Kramm T, Lichtblau M, Marra A, Nagel C, Sablotzki A, Seyfarth HJ, Schranz D, Ulrich S, Hoeper MM, Lange TJ.

Dtsch Med Wochenschr. 2016 Oct;141(S 01):S42-S47. Epub 2016 Oct 19. Review. German.

PMID:
27760449
25.

[Targeted therapy of pulmonary arterial hypertension: Recommendations of the Cologne Consensus Conference 2016].

Hoeper MM, Apitz C, Grünig E, Halank M, Ewert R, Kaemmerer H, Kabitz HJ, Kähler C, Klose H, Leuchte H, Ulrich S, Olsson KM, Distler O, Rosenkranz S, Ghofrani HA.

Dtsch Med Wochenschr. 2016 Oct;141(S 01):S33-S41. Epub 2016 Oct 19. Review. German.

PMID:
27760448
26.

[General and supportive therapy of pulmonary arterial hypertension].

Grünig E, Benjamin N, Krüger U, Kaemmerer H, Harutyunova S, Olsson KM, Ulrich S, Gerhardt F, Neurohr C, Sablotzki A, Halank M, Kabitz HJ, Thimm G, Fliegel KG, Klose H.

Dtsch Med Wochenschr. 2016 Oct;141(S 01):S26-S32. Epub 2016 Oct 19. Review. German.

PMID:
27760447
27.

[Risk stratification and follow-up assessment of patients with pulmonary arterial hypertension: Recommendations of the Cologne Consensus Conference 2016].

Leuchte HH, Ten Freyhaus H, Gall H, Halank M, Hoeper MM, Kaemmerer H, Kähler C, Riemekasten G, Ulrich S, Schwaiblmair M, Ewert R.

Dtsch Med Wochenschr. 2016 Oct;141(S 01):S19-S25. Epub 2016 Oct 19. Review. German.

PMID:
27760446
28.

Evaluation of the pharmacoDYNAMIC effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction : Study protocol for a randomized controlled trial.

Mascherbauer J, Grünig E, Halank M, Hohenforst-Schmidt W, Kammerlander AA, Pretsch I, Steringer-Mascherbauer R, Ulrich S, Lang IM, Wargenau M, Frey R, Bonderman D.

Wien Klin Wochenschr. 2016 Dec;128(23-24):882-889. Epub 2016 Sep 2.

29.

Late outcomes after acute pulmonary embolism: rationale and design of FOCUS, a prospective observational multicenter cohort study.

Konstantinides SV, Barco S, Rosenkranz S, Lankeit M, Held M, Gerhardt F, Bruch L, Ewert R, Faehling M, Freise J, Ghofrani HA, Grünig E, Halank M, Heydenreich N, Hoeper MM, Leuchte HH, Mayer E, Meyer FJ, Neurohr C, Opitz C, Pinto A, Seyfarth HJ, Wachter R, Zäpf B, Wilkens H, Binder H, Wild PS.

J Thromb Thrombolysis. 2016 Nov;42(4):600-9. doi: 10.1007/s11239-016-1415-7.

30.

MR-proADM Predicts Exercise Capacity and Survival Superior to Other Biomarkers in PH.

Kolditz M, Seyfarth HJ, Wilkens H, Ewert R, Bollmann T, Dinter C, Hertel S, Klose H, Opitz C, Grünig E, Höffken G, Halank M.

Lung. 2015 Dec;193(6):901-10. doi: 10.1007/s00408-015-9802-y. Epub 2015 Sep 12.

PMID:
26363916
31.

Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thrombo-embolic pulmonary hypertension: a prospective, randomized, controlled trial.

Ehlken N, Lichtblau M, Klose H, Weidenhammer J, Fischer C, Nechwatal R, Uiker S, Halank M, Olsson K, Seeger W, Gall H, Rosenkranz S, Wilkens H, Mertens D, Seyfarth HJ, Opitz C, Ulrich S, Egenlauf B, Grünig E.

Eur Heart J. 2016 Jan 1;37(1):35-44. doi: 10.1093/eurheartj/ehv337. Epub 2015 Jul 31.

32.

Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease.

Ghofrani HA, Staehler G, Grünig E, Halank M, Mitrovic V, Unger S, Mueck W, Frey R, Grimminger F, Schermuly RT, Behr J.

Pulm Circ. 2015 Jun;5(2):296-304. doi: 10.1086/680214.

33.

Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Marra AM, Egenlauf B, Ehlken N, Fischer C, Eichstaedt C, Nagel C, Bossone E, Cittadini A, Halank M, Gall H, Olsson KM, Lange TJ, Grünig E.

Int J Cardiol. 2015 Sep 15;195:19-26. doi: 10.1016/j.ijcard.2015.05.105. Epub 2015 May 19.

34.

[Dyspnoea in Patients with Pulmonary Hypertension (PH) - a Survey in Spezialized German PH Centres].

Ewert R, Wilkens H, Skowasch D, Reppel M, Bollmann T, Halank M, Held M, Klose H, Gall H, Lange TJ, Opitz CF, Seyfarth HJ, Winkler J.

Pneumologie. 2015 Jun;69(6):361-5. doi: 10.1055/s-0034-1391893. Epub 2015 Apr 21. German.

35.

[Riociguat: stimulator of soluble guanylate-cyclase. New mode of action for the treatment of pulmonary arterial and non operable chronic thromboembolic pulmonary hypertension].

Leuchte HH, Behr J, Ewert R, Ghofrani HA, Grünig E, Halank M, Held M, Klose H, Rosenkranz S, Schermuly RT, Wilkens H, Hoeper MM.

Pneumologie. 2015 Mar;69(3):135-43. doi: 10.1055/s-0034-1391435. Epub 2015 Mar 6. Review. German.

36.

[Imatinib for pulmonary arterial hypertension].

Hoeper MM, Opitz C, Olschewski H, Ulrich S, Speich R, Behr J, Halank M, Wilkens H, Klose H, Lange TJ, Grünig E, Seeger W, Ewert R, Borst MM, Welte T, Rosenkranz S, Ghofrani HA.

Dtsch Med Wochenschr. 2014 Dec;139 Suppl 4:S151-4. doi: 10.1055/s-0034-1387457. Epub 2014 Dec 9. Review. German. No abstract available.

PMID:
25489685
37.

[Quality of life in pulmonal arterial hypertension and in chronic thromboembolic pulmonary hypertension].

Halank M, Speich R, Petkova D, Saxer S, Müller-Mottet S, Hasler E, Kolditz M, Wilkens H, Ehlken N, Lichtblau M, Egenlauf B, Kähler C, Lüneburg N, Mertens D, Schulz U, Barner A, Grünig E, Puhan M, Ulrich S.

Dtsch Med Wochenschr. 2014 Dec;139 Suppl 4:S126-35. doi: 10.1055/s-0034-1387482. Epub 2014 Dec 9. Review. German. No abstract available.

PMID:
25489682
38.

Genetic susceptibility to hepatoxicity due to bosentan treatment in pulmonary hypertension.

Seyfarth HJ, Favreau N, Tennert C, Ruffert C, Halank M, Wirtz H, Mössner J, Rosendahl J, Kovacs P, Wittenburg H.

Ann Hepatol. 2014 Nov-Dec;13(6):803-9.

39.

Response to letters regarding article, "Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)".

Olsson KM, Delcroix M, Ghofrani HA, Tiede H, Huscher D, Speich R, Grünig E, Staehler G, Rosenkranz S, Halank M, Held M, Lange TJ, Behr J, Klose H, Claussen M, Ewert R, Opitz CF, Vizza CD, Scelsi L, Vonk-Noordegraaf A, Kaemmerer H, Gibbs JS, Coghlan G, Pepke-Zaba J, Schulz U, Gorenflo M, Pittrow D, Hoeper MM.

Circulation. 2014 Sep 16;130(12):e110-2. doi: 10.1161/CIRCULATIONAHA.114.010921. No abstract available.

PMID:
25223780
40.

Fingolimod in a patient with heart failure on the background of pulmonary arterial hypertension and coronary artery disease.

Thomas K, Schrötter H, Halank M, Ziemssen T.

BMC Neurol. 2014 Jun 7;14:126. doi: 10.1186/1471-2377-14-126.

41.

Haemoptysis due to pulmonary venous stenosis.

Braun S, Platzek I, Zöphel K, Weise M, Kolditz M, Halank M, Hoeffken G.

Eur Respir Rev. 2014 Jun;23(132):170-9. doi: 10.1183/09059180.00003713. Review. Erratum in: Eur Respir Rev. 2014 Sep;23(133):399.

42.

Tobacco smoke exposure in pulmonary arterial and thromboembolic pulmonary hypertension.

Keusch S, Hildenbrand FF, Bollmann T, Halank M, Held M, Kaiser R, Kovacs G, Lange TJ, Seyfarth HJ, Speich R, Ulrich S.

Respiration. 2014;88(1):38-45. doi: 10.1159/000359972. Epub 2014 May 15.

43.

Fibrinogen plasma concentration is an independent marker of haemodynamic impairment in chronic thromboembolic pulmonary hypertension.

Hennigs JK, Baumann HJ, Lüneburg N, Quast G, Harbaum L, Heyckendorf J, Sydow K, Schulte-Hubbert B, Halank M, Klose H.

Sci Rep. 2014 Apr 28;4:4808. doi: 10.1038/srep04808.

44.

Everolimus in patients with severe pulmonary hypertension: a safety and efficacy pilot trial.

Seyfarth HJ, Hammerschmidt S, Halank M, Neuhaus P, Wirtz HR.

Pulm Circ. 2013 Sep;3(3):632-8. doi: 10.1086/674311. Epub 2013 Nov 19.

45.

Economic evaluation of exercise training in patients with pulmonary hypertension.

Ehlken N, Verduyn C, Tiede H, Staehler G, Karger G, Nechwatal R, Opitz CF, Klose H, Wilkens H, Rosenkranz S, Halank M, Grünig E.

Lung. 2014 Jun;192(3):359-66. doi: 10.1007/s00408-014-9558-9. Epub 2014 Mar 8.

PMID:
24609926
46.

Anxiety and depression disorders in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Harzheim D, Klose H, Pinado FP, Ehlken N, Nagel C, Fischer C, Ghofrani A, Rosenkranz S, Seyfarth HJ, Halank M, Mayer E, Grünig E, Guth S.

Respir Res. 2013 Oct 9;14:104. doi: 10.1186/1465-9921-14-104.

47.

Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA).

Olsson KM, Delcroix M, Ghofrani HA, Tiede H, Huscher D, Speich R, Grünig E, Staehler G, Rosenkranz S, Halank M, Held M, Lange TJ, Behr J, Klose H, Claussen M, Ewert R, Opitz CF, Vizza CD, Scelsi L, Vonk-Noordegraaf A, Kaemmerer H, Gibbs JS, Coghlan G, Pepke-Zaba J, Schulz U, Gorenflo M, Pittrow D, Hoeper MM.

Circulation. 2014 Jan 7;129(1):57-65. doi: 10.1161/CIRCULATIONAHA.113.004526. Epub 2013 Sep 30.

PMID:
24081973
48.

Assessment and prognostic relevance of right ventricular contractile reserve in patients with severe pulmonary hypertension.

Grünig E, Tiede H, Enyimayew EO, Ehlken N, Seyfarth HJ, Bossone E, D'Andrea A, Naeije R, Olschewski H, Ulrich S, Nagel C, Halank M, Fischer C.

Circulation. 2013 Oct 29;128(18):2005-15. doi: 10.1161/CIRCULATIONAHA.113.001573. Epub 2013 Sep 20.

PMID:
24056689
49.

Pulmonary hypertension in patients with idiopathic pulmonary fibrosis - the predictive value of exercise capacity and gas exchange efficiency.

Gläser S, Obst A, Koch B, Henkel B, Grieger A, Felix SB, Halank M, Bruch L, Bollmann T, Warnke C, Schäper C, Ewert R.

PLoS One. 2013 Jun 20;8(6):e65643. doi: 10.1371/journal.pone.0065643. Print 2013.

50.

Exercise capacity affects quality of life in patients with pulmonary hypertension.

Halank M, Einsle F, Lehman S, Bremer H, Ewert R, Wilkens H, Meyer FJ, Grünig E, Seyfarth HJ, Kolditz M, Wieder G, Höffken G, Köllner V.

Lung. 2013 Aug;191(4):337-43. doi: 10.1007/s00408-013-9472-6. Epub 2013 May 17.

PMID:
23681593

Supplemental Content

Loading ...
Support Center